On the 24th, the bio company Nature Cell listed on the KOSDAQ market recorded its upper limit in the early morning session. This surge in buying is interpreted as a response to news that Nature Cell's degenerative arthritis stem cell treatment "Joint Stem" has been designated as an innovative treatment by the U.S. Food and Drug Administration (FDA).
As of 9:25 a.m. on the same day, Nature Cell was trading at 22,200 won, up 29.75% from the previous trading day.
Earlier, Nature Cell noted that on the 21st, after the market closed, "Joint Stem" was designated as the first innovative treatment in cell therapy in Korea by the FDA.
According to Nature Cell, "Joint Stem" is the world's first adipose-derived mesenchymal stem cell therapy for patients with severe knee osteoarthritis. It is explained that a single local injection into the knee joint cavity can result in pain reduction and improved joint function effects through cartilage regeneration, lasting for at least three years.
When designated as an innovative treatment, it will receive intensive support from the FDA, including fast track designation, which increases the likelihood of product approval.